From: Association of renal resistive indices with kidney disease progression and mortality
Univariate analysis | |||
---|---|---|---|
HR | 95% Confidence Interval | P | |
RRI | 1.08 | 1.04–1.11 | < 0.001 |
Age | 1.04 | 1.02–1.07 | 0.001 |
Sex ( Ref: Male) | 1.60 | 0.89–2.87 | 0.118 |
Diabetes | 1.40 | 0.82–2.39 | 0.224 |
Dyslipidemia | 0.77 | 0.41–1.44 | 0.410 |
Obesity | 0.75 | 0.42–1.35 | 0.334 |
CAD | 2.19 | 1.26–3.80 | 0.008 |
Heart failure | 2.28 | 1.11–4.68 | 0.025 |
Stroke | 0.54 | 0.07–3.96 | 0.546 |
eGFR, mL/min | 0.97 | 0.96–0.98 | < 0.001 |
ACR, g/g | 1.13 | 0.99–1.28 | 0.058 |
RAAS inhibitors | 0.41 | 0.24–0.69 | 0.001 |
Statins | 0.63 | 0.37–1.08 | 0.093 |
Beta-blockers | 1.93 | 1.08–3.46 | 0.027 |
Antiaggregants | 1.46 | 0.85–2.51 | 0.176 |
PPIs | 0.69 | 0.36–1.34 | 0.273 |
Number of antihypertensives | 0.86 | 0.64–1.16 | 0.325 |
BP control < 140/90 | 0.90 | 0.53–1.54 | 0.703 |
HbA1c reduction in patients with diabetes | 0.99 | 0.49–2.01 | 0.997 |
Salt reduction | 0.68 | 0.38–1.23 | 0.207 |
Smoking cessation in smokers | 0.34 | 0.08–1.43 | 0.141 |
Number of consultations | 0.99 | 0.96, 1.02 | 0.394 |